" /> Everolimus - CISMeF





Preferred Label : Everolimus;

NCIt synonyms : 42-O-(2-Hydroxy)ethyl Rapamycin; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone;

NCIt related terms : RAD001; Afinitor;

NCIt definition : A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05);

Alternative definition : NCI-GLOSS: A drug used to treat advanced kidney cancer that did not respond to treatment with certain other anticancer drugs. It is also being studied in the treatment of other types of cancer. Afinitor stops cancer cells from dividing and may block the growth of new blood vessels that tumors need to grow. It also decreases the body's immune responses. It is a type of immunosuppressant and a type of antiangiogenesis agent.;

UNII : 9HW64Q8G6G;

InChIKey : HKVAMNSJSFKALM-GKUWKFKPSA-N;

CAS number : 159351-69-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 159351-69-6 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Certican; Afinitor; Zortress; Votubia;

Molecule name : RAD 001; RAD-001;

Chemical formula : C53H83NO14;

NSC code : 733504;

Codes from synonyms : CDR0000386203; CDR0000639748; CDR0000639749; 50567; 202;

Details


You can consult :


Nous contacter.
10/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.